Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of trimethylamine oxide as biomarker of cerebral apoplexy

A technology of trimethylamine oxide and stroke, applied in the field of biomedicine, can solve the problems such as the relationship between TMAO and the risk of stroke, and the risk of cardiovascular events that are not further confirmed, and achieve the effect of reducing medical costs and preventing stroke.

Inactive Publication Date: 2019-12-10
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] According to the latest research progress at home and abroad, the level of blood TMAO is currently believed to be a risk factor for atherosclerosis, and the increase of blood TMAO level may lead to an increase in the overall risk of cardiovascular events (mainly referring to myocardial infarction and cardiovascular death). The study is limited to this, without further confirming the relationship between TMAO and the risk of stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trimethylamine oxide as biomarker of cerebral apoplexy
  • Application of trimethylamine oxide as biomarker of cerebral apoplexy
  • Application of trimethylamine oxide as biomarker of cerebral apoplexy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Effect of TMAO level on mouse vascular endothelial function

[0022] Experimental method: 20 8-week-old healthy female C57BL / 6J mice (purchased from the Animal Experiment Center of the Third Military Medical University) were fasted overnight and divided into a blank group and a choline group, and the choline group was given a single intragastric administration Choline (choline, C7017 was purchased from Sigma, USA, 400mg / kg), the blank group was given the same dose of normal saline, and blood samples were collected from the tail vein 4 hours after gavage, and the plasma was separated by centrifugation and stored at -80°C for use . The blank group and the choline group were given normal saline and choline by intragastric administration every day, and blood samples were collected from the tail vein after 8 weeks, and the plasma was separated by centrifugation and stored at -80°C until use.

[0023] Detection method: LC / MS analysis was used to detect the level o...

Embodiment 2

[0032] Example 2. Effect of TMAO level on apoE- / -mice aortic atherosclerosis

[0033] Experimental method: 16 8-week-old healthy male apoE- / - mice (purchased from the Experimental Animal Center of Peking University Health Science Center) were randomly divided into a blank group and a choline group, and the choline group was given choline (choline, C7017 was purchased from Sigma, USA, 400mg / kg). The blank group was given the same dose of normal saline, and the blank group and the choline group were given normal saline and choline by gavage every day. They were killed after 16 weeks of administration, and blood was collected from the orbit.

[0034] Detection method: MDA was determined by thiobarbituric acid method, continuous paraffin sections of the aortic root, 5um, 40 pieces, one piece was taken every 5 pieces, a total of 8 sections were taken for HE staining, and AS plaque was determined by computer pathological image analysis software Block size; streptomycin and biotin co...

Embodiment 3

[0040] Example 3: A nested case-control study on the relationship between serum TMAO level and stroke risk (one) method

[0041] The study period was from 2008 to 2013, and the selection criteria for patients (subjects) were: 1) aged 45 to 75 years (inclusive), male or female; 2) meeting the diagnostic criteria for essential hypertension, excluding secondary hypertensive Blood pressure; 3) No history of stroke or myocardial infarction; 4) Voluntary participation and signed informed consent. The number of cases was 20,702, of which the enalapril folic acid group (group A) and the enalapril group (group B) each accounted for half, and the patients in the two groups took "Yiye" (10mg / 0.8mg) or enalapril Li tablets (10mg) were taken once a day, 1 tablet each time, and were taken continuously for 4.5 years (median). The primary efficacy indicator (primary endpoint) was the first symptomatic stroke (ischemic or hemorrhagic, excluding subarachnoid hemorrhage), and the secondary effi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of trimethylamine oxide (TMAO) as a biomarker for cerebral apoplexy risk assessment and prognostic judgment. The invention also relates to an application of trimethylamine oxide as a drug screening target for screening drugs for treating cerebral apoplexy. The invention provides an application of trimethylamine oxide in preparation of a kit for diagnosing cerebral apoplexy and / or evaluating the risk of suffering from cerebral apoplexy, provides an application of trimethylamine oxide in preparation of a kit for evaluating the treatment effect of cerebralapoplexy or judging prognosis of cerebral apoplexy, and further provides an application of trimethylamine oxide in preparation of a kit for screening drugs for preventing or treating cerebral apoplexy. According to the invention, the accuracy of current cerebral apoplexy risk prediction can be improved, and the improvement of cerebral apoplexy prevention measures, prognosis judgment and development of therapeutic drugs are facilitated.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a new application of trimethylamine oxide (TMAO), in particular to an application as a biomarker for stroke risk assessment and prognosis judgment. The invention also relates to the use of trimethylamine oxide as a drug screening target for screening drugs for treating cerebral apoplexy. Background technique [0002] Stroke has the characteristics of high morbidity, high disability and death rate, and high recurrence rate, and the treatment methods are limited. It is a serious disease that endangers human health. Therefore, the prediction of stroke incidence and the control of risk factors are particularly important, and the prediction is Based on a full understanding of risk factors. The risk factors of stroke are divided into two categories: controllable and uncontrollable, the former such as hypertension, hyperlipidemia, diabetes, obesity or overweight, smoking and alcohol addiction,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/72
CPCG01N30/02G01N30/72
Inventor 聂静秦献辉朱风新霍勇徐希平张磊周苗苗
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com